

MoonLake Immunotherapeutics

U.S. Securities Litigation

MoonLake Immunotherapeutics (NASDAQ: MLTX): MoonLake Immunotherapeutics (“MoonLake” or the “Company”) is being investigated for violations of the federal securities laws in connection with potential false and misleading statements made to investors and a subsequent significant price decline in the stock.

If you incurred losses on your investments in MoonLake, you are encouraged to submit your information.

Why Is MoonLake being Investigated?

MoonLake is a clinical stage biotechnology company focusing on therapies to address inflammatory skin and joint diseases. During the relevant period, MoonLake conducted highly anticipated Phase 3 VELA trials for sonelokimab, an investigational therapeutic designed to treat inflammatory diseases, in adult participants with moderate to severe hidradenitis suppurativa.

On September 29, 2025, before market hours, MoonLake reported its week 16 results of the VELA Phase 3 trials. The Company reported disappointing results for both trials, calling into question the drug’s chances for regulatory approval and commercial viability. On this news, the price of MoonLake stock fell \$55.75 per share, or nearly 90%, from \$61.99 per share on September 28, 2025, to \$6.24 per share on September 29, 2025.

What Are My Rights?

If you incurred losses on your investments in MoonLake, you are encouraged to submit your information using the form on this page to speak with an attorney about your rights.

You can also contact:

Ross Shikowitz

ross@bfalaw.com

212.789.3619

All representation is on a contingency fee basis. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by *Chambers USA*, *The Legal 500*, and *ISS SCAS*, and its attorneys have been named “Elite Trial Lawyers” by the *National Law Journal*, among the top “500 Leading Plaintiff Financial Lawyers” by *Lawdragon*, “Titans of the Plaintiffs’ Bar” by *Law360* and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over \$900 million in value from Tesla, Inc.’s Board of Directors, as well as \$420 million from Teva Pharmaceutical Ind. Ltd.

Attorney advertising. Past results do not guarantee future outcomes.